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Abstract
Aims: Pelvic lymph node (PLN) radiotherapy for high-risk prostate cancer is limited by late gastrointestinal toxicity. Application of rectal and bowel constraints
may reduce risks of side-effects. We evaluated associations between intensity-modulated radiotherapy (IMRT) dose-volume data and long-term gastrointestinal
toxicity.
Materials and methods: Data from a single-centre dose-escalation trial of PLN-IMRT were analysed, including conventionally fractionated (CFRT) and hypo-
fractionated (HFRT) radiotherapy schedules. Associations between volumes of rectum and bowel receiving speciﬁed doses and clinician- and patient-reported
toxicity outcomes were investigated independently. A metric, dmedian (dM), was deﬁned as the difference in the medians of a volume between groups with and
without toxicity at a speciﬁed dose and was used to test for statistically signiﬁcant differences.
Results: Constraints were respected in most patients and, when exceeded, led to higher rates of gastrointestinal toxicity. Biologically relevant associations
between rectum dose-points and toxicity were more numerous with both mild and moderate toxicity thresholds, but statistical signiﬁcance was limited after
correction for false discovery rate. Rectal V50Gy (CFRT) associated with grade 2þ bleeding; bowel V43Gy and V47 (HFRT/4 days/week schedule) associated with
patient-reported loose stools and diarrhoea, respectively. Further investigation showed that CFRT patients with rectal bleeding had a mean rectal V50Gy above
the treatment planning constraint.
Conclusions: When dose-volume parameters are kept below tight constraints, toxicity is low. Residual dosimetry loses much of its predictive power for
gastrointestinal toxicity in the setting of PLN-IMRT for prostate cancer. We have benchmarked dose-volume constraints for safely delivering PLN-IMRT using
CFRT or HFRT.
 2019 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Radiotherapy in Advanced Localised Prostate Cancer, Clinical Oncology, hLate toxicity, starting 3months to years after treatment, is of
particular concern as pelvic lymph node (PLN) radiotherapy
may increase gastrointestinal side-effects [1e4].
The risk of gastrointestinal toxicity is judged with dose-
volume histograms. However, there is limited consensus
regarding their prognostic value, particularly in the era of
dose-volume constraint-based inverse-planned radio-
therapy. Although concordant at higher doses, studies show
different dose-volume histogram metrics as predictive of
rectal bleeding and it is difﬁcult to ﬁnd consistentd. This is an open access article under the CC BY-NC-ND license (http://
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Treatment planning dose constraints have been developed
tominimise risks. Although the QUANTECmeta-analyses on
gastrointestinal dose constraints provided evidence-based
guidance for radiotherapy planning, they were based on
studies using three-dimensional conformal radiotherapy
[5,9]. Intensity-modulated radiotherapy (IMRT) may have
changed toxicity patterns and relationships with dosimetry
[5,9]. Other proposed models of risk evaluation have not
been introduced in the clinic [10e12].
We investigated relationships between dose-volume
constraints and late gastrointestinal toxicity in patients
prospectively treated with conventionally fractionated
(CFRT) or hypofractionated (HFRT) prostate and pelvic IMRT
for high-risk PCa in a phase I/II study [3].Materials and methods
Patients and Data
Patients treated in a previously reported phase I/II study
of prostate and pelvic IMRT for high-risk PCa (IMRT-PCa
trial) were eligible [3]. The trial accrued 473 patients with
high-risk PCa between August 2000 and September 2013.
CFRT was delivered to the prostate and seminal vesicles
(70e74 Gy in 35e37 fractions) and 50, 55 or 60 Gy to the
PLN concomitantly over 7e7.4 weeks. Two further cohorts
received HFRT, with 60 Gy (20 fractions) delivered to the
prostate and seminal vesicles and 47 Gy to the PLN in either
4 (5 days/week, HFRT-5D) or 5 weeks (4 days/week, HFRT-
4D). The change to a 5 week schedule (which is an exten-
sion of the 4 week schedule to 5 weeks by delivering four
instead of ﬁve fractions/week) occurred because of docu-
mented increases in short-lasting acute gastrointestinal
toxicity also observed in other studies [3,13,14]. All patients
received long-course androgen deprivation therapy.
Only patients with both toxicity and complete dosimetric
data were included. Patients with <2 years of follow-up
data at the time of analysis were excluded.
Dosimetric Variables
Dosimetric data were obtained from prostate and pelvic
node radiotherapy forms, used to assess the clinical suit-
ability of radiotherapy plans according to deﬁned dose
constraints (see supplementary Table SUPP-1). Where un-
available, datawere obtained from original treatment plans.
Optimal and mandatory bowel constraints were derived
from dose levels related to Radiation Therapy Oncology
Group (RTOG) grade 1 and 2 in previous reports [15].
Rectal dose constraints were derived by pragmatically
adapting available evidence at the time of study design
[16,17]. Constraints weremodiﬁed for HFRT in proportion to
the prescribed dose.
Rectum and bowel were contoured as solid organs ac-
cording to a previously published protocol (see
supplementary text) [3]. Data consisted of absolute rectum
and bowel volumes (cm3), and volumes of bowel (cm3) andPlease cite this article as: Ferreira MR et al., Dosimetry and Gastrointes
Radiotherapy in Advanced Localised Prostate Cancer, Clinical Oncology, hrectum (% of volume) receiving the constraint dose or
higher, henceforth referred to as (a)V(x), where (x) is the
respective dose (Gy) and (a) the identiﬁer for rectum (r) or
bowel (b).
Radiation-induced Gastrointestinal Toxicity Data
Clinical data were collected at 6-month intervals up to 5
years after radiotherapy and yearly thereafter. Only data
collected 6 months after radiotherapy were used. In order
to capture a comprehensive record of toxicity, three inter-
nationally accepted toxicity scales were used [18]. They
were the European Organization for Research and Treat-
ment of Cancer (EORTC)/RTOG and the Late Effects Normal
Tissue Task Force-Subjective, Objective, Management, An-
alytic (LENT-SOMA) clinician-reported late toxicity scales
and the UCLA Prostate Cancer Index (UCLA-PCI) patient-
reported outcomes scaleebowel subset (questions 17e21)
[19e21].
Analysis was undertaken endpoint-by-endpoint. Pa-
tients with positive baseline side-effect scores were
excluded from analysis for that speciﬁc endpoint only. For
example, if a patient had rectal bleeding before radio-
therapy, he was excluded from the rectal bleeding analysis
but not from tenesmus and other endpoints. We also
excluded toxicity endpoints that had an incidence of 5% in
the entire cohort.
Patients were divided by peak toxicity using mild and
moderate/severe thresholds for each endpoint (see
supplementary Table SUPP-2) [21].
Associations were studied between dose-points and all
toxicity outcomes in three different scales by cohort. We do
not report amalgamated results of all cohorts given that
constraints were not equivalent radiobiologically and
because this strategy enables the study of differential re-
lationships between CFRT and HFRT schedules.
Statistical Considerations
Dose-volume metrics (dose-points) where 80% of pa-
tients had a value of 0 were excluded. They were rV75/bV65
(CFRT) and rV63/bV55 (HFRT). Bowel metrics where the
mean volume was <2 cm3 were also excluded. They were
bV60 (CFRT) and bV51 (HFRT).
To assess biological signiﬁcance in this large dataset, a
measure of inter-group difference was created. This metric,
henceforth named ‘d median’ (dM), is deﬁned as:
dM ¼ median VðxÞ ðsymptomatic groupÞ
median VðxÞ ðnon symptomatic groupÞ
where V(x) is the dose-point of interest. Therefore, dM in-
dicates if volumes appear greater in the group with or
without toxicity (see supplementary Figure SUPP-1). Sta-
tistical signiﬁcance was assessed using the Wilcoxon rank
sum test.
Associations between dose-points and toxicity were
sought by testing all dose-points against each endpoint in
all toxicity scales, leading to the use of multiple statisticaltinal Toxicity Relationships in a Phase II Trial of Pelvic Lymph Node
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was used to correct for false discovery rate (FDR) as per the
following equation [22]:Alpha level of significance ¼ Target alpha level
n rank number of pair by degree of significanceþ 1where n is the number of tested hypotheses (number of
tests done by toxicity scale per cohort, including both
toxicity thresholds) and the target alpha level is 0.05. It
follows that all P values reported in this article are ‘uncor-
rected’, as the Holm method uses the corrected alpha level
of signiﬁcance as a threshold to accept or reject the null
hypothesis. A positive result is deﬁned as a positive dM (>0)
where statistical signiﬁcance was reached.
Where positive associations resilient to FDR correction
were found, new constraints were derived using receiver
operating characteristic (ROC) curves [23]. Odds ratios of
toxicity were calculated for protocol and new constraints
and signiﬁcance assessed with Fisher’s exact test.
Analysis was carried out in Excel and R [24].Results
Patient Characteristics
Of 473 patients recruited in the trial, 26 had been
recruited <2 years before data lock and thus did not have
long-term (2 years) toxicity data available and wereTable 1
Patient demographics
All cohorts CFR
No. patients with toxicity follow-up
data 2 years (no. excluded due to
follow-up data <2 years)
LENT-SOMA: 414 (54)
RTOG: 414 (63)
UCLA-PCI: 369 (73)
LEN
RTO
UCL
No. patients analysed (no. excluded
due to incomplete dosimetric data)
LENT-SOMA: 368 (46)
RTOG: 368 (46)
UCLA-PCI: 325 (44)
LEN
RTO
UCL
No. patients by prescription dose to
the PLN n (%)
N/A 50 G
55 G
60 G
Age at treatment
Mean (range)
65 (45e82) 64 (
Follow-up (years)
Median (IQR)
5 (4e7) 7 (5
Rectum volume (cm3)
Median (IQR)
66.7 (50.6e86.1) 64.7
Bowel volume (cm3)
Median (IQR)
478.2 (347.7e640.6) 463
CFRT, conventionally fractionated radiotherapy; HFRT-4D, hypofract
radiotherapy (5 days/week); RTOG, Radiation Therapy Oncology Group
LENT-SOMA.
UCLA-PCI.
* Patients had planned dose reductions due to difﬁculties in meeting
Please cite this article as: Ferreira MR et al., Dosimetry and Gastrointes
Radiotherapy in Advanced Localised Prostate Cancer, Clinical Oncology, hexcluded. Of the remaining 447 patients, 426 had been
treated according to protocol and long-term toxicity data
were available for 421. Dosimetric data were not retrievable
for seven patients and thus 414 (98% of patients with 2
year toxicity follow-up data) were included for analysis.
Proportions of patients with and without toxicity were
comparable with those observed in the main analysis of the
IMRT for Prostate Cancer trial, except for UCLA-PCI bowel
problem (see supplementary Table SUPP-4). This discrep-
ancy is explained by our methodology, as patients with a
moderate/severe bowel problem at baseline (i.e. before the
start of radiotherapy) were excluded in an endpoint-by-
endpoint basis to obtain an accurate representation of
gastrointestinal problems caused by radiotherapy. Howev-
er, all patient- and clinician-reported gastrointestinal
toxicity rates are comparable to previously reported anal-
ogous studies [25].
Groups were reported by prostate radiotherapy frac-
tionation (Table 1) because dose-volume constraints were
not equivalent radiobiologically [26]. This approach allows a
comparison of differences between CFRT and HFRT in terms
of relationships between dosimetry and toxicity, which was
one of our objectives.T HFRT-4D HFRT-5D
T-SOMA: 234 (42)
G:234 (51)
A-PCI: 213 (43)
LENT-SOMA: 122 (7)
RTOG: 122 (7)
UCLA-PCI: 103 (20)
LENT-SOMA: 58 (5)
RTOG: 58 (5)
UCLA-PCI: 53 (10)
T-SOMA: 205 (29)
G: 205 (29)
A-PCI: 185 (28)
LENT-SOMA: 114 (8)
RTOG: 114 (8)
UCLA-PCI: 95 (8)
LENT-SOMA: 49 (9)
RTOG: 49 (9)
UCLA-PCI: 45 (8)
y: 15 (7.3%)
y: 52 (25.4%)
y: 138 (67.3%)
47 Gy: 103 (90.3%)
43 Gy*: 11 (9.7%)
47 Gy: 46 (93.9%)
43 Gy*: 3 (6.1%)
45e82) 67 (47e80) 67 (47e79)
e9) 4 (3e4) 5 (5e5.5)
(51.1e87.5) 63.5 (44.3e77.0) 72.9 (58.1e94.3)
.2 (343.9e649.0) 478.3 (369.9e632.4) 519.1 (371.3e616.9)
ionated radiotherapy (4 days/week); HFRT-5D, hypofractionated
; PLN, pelvic lymph nodes; IQR, interquartile range.
dose-volume constraints.
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with Toxicity
We previously published encouraging toxicity out-
comes of dose-escalated and hypofractionated PLN-IMRT
in the IMRT for Prostate Cancer trial [3]. The trial pro-
tocol used strict dose-volume constraints for rectum and
bowel (see supplementary Table SUPP-1). Application of
dose-volume constraints may reduce gastrointestinal
toxicity [27]. We therefore ﬁrst hypothesised that rates
of patients failing constraints were low in our dataset.
We also explored relationships between the number of
failed constraints and RTOG-scored maximum peak
toxicity.
Rectum
Most patients met all constraints in all cohorts
(Figure 1A, supplementary Figure SUPP-2A, Tables SUPP-
5eSUPP-7). However, the rV50 constraint was exceeded in
26% in the CFRT cohort. Patients exceeding rectal con-
straints experienced more toxicity, particularly with CFRT,
but this pattern was also reproduced in other cohorts
(Figure 1D).0
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Fig 1. Rectum and bowel constraints exceeded and relationships with
exceeded rectal (A), bowel mandatory (B) and optimal (C) constraints; by c
(D), bowel mandatory (E) and optimal (F) constraints exceeded; by cohort
Radiation Therapy Oncology Group (RTOG) grade (rectum: maximum sco
rectal ulcer; bowel: maximum score of bowel frequency, diarrhoea, bowe
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Optimal/mandatory bowel constraints were deﬁned by
average volumes correlating with no/mild diarrhoea,
respectively, in previous reports [15]. Although optimal
constraints were exceeded frequently, mandatory con-
straints were generally respected (Figure 1B, C,
supplementary Figure SUPP-2B, Tables SUPP-8eSUPP-10).
As with rectum, a pattern whereby patients exceeding
bowel constraints experience more toxicity was observed.
This pattern was most evident in the CFRT cohort and
mandatory constraints (Figure 1E, F).
Associations between Dosimetric Parameters and Toxicity
We used the dM measure to assess differences in vol-
umes between groups of patients with and without toxicity
and assessed their statistical signiﬁcance stringently. For
most endpoints, dM was small: 79% and 74.6% of dM were
3% of rectum or 10 cm3 of bowel volumes, respectively
(supplementary Table SUPP-11), reﬂecting small differences
in median dose-point values between patients with and
without toxicity. Five of 63 (8%) relationships suggested had
negative dM values, but were not robust to FDR correction.4 5
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(bowel). Supplementary Tables R1e9 (rectum) and B1e9
(bowel) summarise all ﬁndings.
Rectum
In the CFRT cohort, rV50 was higher in patients with
moderate/severe (grade 2þ) rectal bleeding in both RTOG
(P ¼ 0.00008) and LENT-SOMA (P ¼ 0.00004) scales. These
were the only results for rectum that were resilient to Holm
correction (Table 2). rV50 was also higher in patients with
mild (grade 1þ) LENT-SOMA bleeding and bowel problem,
albeit non-signiﬁcantly. In HFRT cohorts, rV51/rV55 (HFRT-
4D) and rV59 (HFRT-5D) associated with bleeding, albeit
non-signiﬁcantly.
Bowel
In the HFRT-4D cohort, bV43 and bV47 were higher in
patients with mild self-reported loose stools (P ¼ 0.0005)
and RTOG-scored diarrhoea (P ¼ 0.002), respectively. These
were the only results resilient to FDR correction (Table 3).
However, bV39 also associated non-signiﬁcantly with mild
self-reported loose stools and bV43 also associated non-
signiﬁcantly with diarrhoea-related toxicity endpoints, as
did bV39/bV43 and bV45/bV55/bV60 in the HFRT-5D and
CFRT cohorts, respectively.Relationships between Signiﬁcant Associations and Dose-
volume Constraints
Three signiﬁcant associations were detected in our
dataset: rV50 (CFRT) and rectal bleeding, as well as bV43/
bV47 (HFRT4D) with loose stools/diarrhoea.We examined if
relationships with constraints were present and explored
whether different constraints could be derived from our
dataset.
CFRT/rV50 and rectal bleeding
Mean rV50 was 65%/54% and 66%/54% for patients
treated with CFRT with/without grade 2þ RTOG and LENT-
SOMA bleeding, respectively. Interestingly, in both cases,
mean rV50 for patients with bleeding was above the rV50
constraint (Figure 2AeF). Such a relationship was not
observed for any other rectal endpoint in relation to
bleeding in any cohort. The rV50-CFRT constraint derived
using this dataset was 59% (AUC: 0.79; 95% conﬁdence in-
terval 0.69e0.89; supplementary Table SUPP-12). Odds ra-
tios for toxicity using protocol or new constraints were
similar (supplementary Table SUPP-13), indicating that the
protocol constraint was adequate for preventing toxicity if
respected.
HFRT-4D/bV43 and loose stools
Although mean bV43 was higher in patients with mild
self-reported loose stools (36.9 cm3) than in patients
without loose stools (34.3 cm3), they were both under the
mandatory (110 cm3) and over the optimal (17 cm3) con-
straints (Figure 2GeI). bV39 was non-signiﬁcantly higher
than mandatory constraints in patients with loose stools,
unlike patients without loose stools. Mean volumes forPlease cite this article as: Ferreira MR et al., Dosimetry and Gastrointes
Radiotherapy in Advanced Localised Prostate Cancer, Clinical Oncology, hbV47ebV55 overlapped between groups, similar to the
HFRT-5D cohort. With CFRT, there were no differences be-
tween groups. The bV43-HFRT constraint derived using this
dataset was 24 cm3 (AUC: 0.73; 95% conﬁdence interval
0.62e0.84; see supplementary Table SUPP-12). Odds ratios
using protocol constraints could not be calculated, as all
patients met the constraint. However, for the new
constraint, the odds ratio was 3.81 (1.59e9.80), indicating
that it may be useful (see supplementary Table SUPP-13).
HFRT-4D/bV47 and diarrhoea
With HFRT-4D, the mean bV47 was 4.49 cm3 in patients
with and 2.80 cm3 in patients without mild (grade 1þ)
RTOG diarrhoea. These values are below the mandatory (28
cm3) and optimal (14 cm3) constraints for bV47
(Figure 2JeL). Similar differences between these groups
were also detected for bV39 and bV43, albeit non-
signiﬁcantly. Such patterns were not observed in other co-
horts. The bV47 constraint derived using this dataset was
2.15 cm3 (AUC: 0.69; 95% conﬁdence interval 0.59e0.79; see
supplementary Table SUPP-12). Odds ratios using protocol
and new constraints were 5.51 (1.79e21.49) and 9.40
(3.24e32.59). This result indicates that failing to meet
either constraint predicts for higher toxicity levels, although
the new constraint may be more robust (see supplementary
Table SUPP-13).Discussion
Late gastrointestinal toxicity limits high-dose pelvic
radiotherapy. Rectum and bowel dose-volume constraints,
designed to minimise gastrointestinal side-effects, are
increasingly important as inverse-planned IMRT becomes
the primary radiotherapy technique for PCa. Several efforts
have been made to detect thresholds below which proba-
bilities of gastrointestinal toxicity are low [5,9,16,17,27e29].
We acknowledge limitations in our study. Planning
computed tomography is a snapshot of a moving organ,
especially for non-rectal bowel. By contouring bowel loops
proximal to the rectum, different organs are included (sig-
moid, colon, jejunum/ileum). However, although
segmented bowel outlining is increasingly used in research
and has been adopted by some centres, RTOG guidelines
recommend that whole bowel (i.e. unsegmented) should be
outlined for genitourinary tumours, reﬂecting general
clinical practice [30]. We also recognise that the pelvic
doses studied are non-standard, as we used data derived
from an IMRT dose-escalation trial [3]. However, PLN-IMRT
may become a standard option pending deﬁnitive results of
ongoing phase III trials. Irrespective of this, our analysis
allows an understanding of modern relationships between
dosimetry and toxicity in a mature dataset.
Our approach makes comparisons between fractionation
schedules possible, which was one of our objectives. How-
ever, in practice, it would be imprecise to pool all cohorts
into a single dose-equivalent dataset, due to three factors:
(1) a/b ratios are not available for most of the symptoms we
studied, (2) there could be imprecisions related to timetinal Toxicity Relationships in a Phase II Trial of Pelvic Lymph Node
ttps://doi.org/10.1016/j.clon.2019.02.012
Table 2
Positive associations between rectum dosimetry/toxicity
Clinician-reported toxicity
Cohort Threshold LENT-SOMA % patients
with toxicity
RTOG % of patients
with toxicity
CFRT M rV60 and mucosal loss (P[ 0.005, dM[ 3.3) 21% rV60 and bowel frequency
(P ¼ 0.01, dM ¼ 3.85)
38%
rV65 and mucosal loss (P[ 0.003, dM[ 4.3) 21%
rV50 and bleeding (P ¼ 0.04, dM ¼ 20.25) 22%
rV60 and sphincter control (P[ 0.008, dM[
3.21)
18%
rV65 and sphincter control (P ¼ 0.04, dM ¼ 4.1) 18%
MS rV50 and bleeding (P ¼ 0.00004, dM ¼ 8.5) 8% rV50 and rectal bleeding
(P ¼ 0.00008, dM ¼ 7.1)
10%
rV60 and mucosal loss (P[ 0.003, dM[ 4.95) 6%
rV65 and mucosal loss (P[ 0.007, dM[ 5.54) 6%
rV60 and bleeding (P ¼ 0.04, dM ¼ 5.23) 8%
HFRT-4D M rV51 and mucosal loss (P ¼ 0.04, dM ¼ 2.83) 22% rV51 and rectal bleeding
(P ¼ 0.02, dM ¼ 3.13)
44%
rV55 and mucosal loss (P ¼ 0.03, dM ¼ 3.9) 22% rV55 and rectal bleeding
(P [ 0.005, dM[ 4.15)
44%
rV59 and bleeding management (P ¼ 0.03,
dM ¼ 2.43)
14%
MS N/A N/A
HFRT-5D M rV51 and tenesmus (P ¼ 0.01, dM ¼ 5.91) 39% rV59 and proctitis
(P [ 0.002, dM[ 2.3)
55%
rV55 and tenesmus (P ¼ 0.01, dM ¼ 3.74) 39%
rV59 and tenesmus (P ¼ 0.01, dM ¼ 2.25) 39%
rV59 and frequency (P ¼ 0.05, dM ¼ 1.86) 41%
MS rV59 and bleeding (P ¼ 0.04, dM ¼ 2.66) 26% N/A
rV59 and mucosal loss (P ¼ 0.02, dM ¼ 3.9) 6%
Patient-reported toxicity
Urgency Loose stools Distress Crampy pain Problem
Threshold/ M MS M MS M MS M MS M MS
Cohort Y
CFRT rV50
(P ¼ 0 .003,
dM ¼ 4.5)
rV50
(P ¼ 0.04,
dM ¼ 2.75)
N/A N/A N/A N/A rV50
(P ¼ 0.03,
dM ¼ 3.2)
N/A rV50
(P ¼ 0.03,
dM ¼ 2.35)
N/A
% patients
with toxicity
38% 27% e e e e 19% e 44% e
HFRT-4D N/A N/A rV43
(P ¼ 0.03,
dM ¼ 4.56)
N/A N/A N/A N/A N/A N/A N/A
% patients
with toxicity
e e 43% e e e e e e e
HFRT-5D N/A N/A N/A rV59
(P ¼ 0.04,
dM ¼ 4)
N/A N/A N/A rV43
(P ¼ 0.01,
dM ¼ 5.2)
N/A N/A
% patients
with toxicity
e e e 20% e e e 15% e e
Where N/A is reported, no positive associations were found. Where P  0.01, results are in bold. Where results were signiﬁcant after Holm
correction, results are bold and italicized. M¼mild threshold (symptomatic patients are deﬁned as having mild or worse symptoms). MS¼
moderate/severe (symptomatic patients are deﬁned as having moderate or worse symptoms). % of patients with toxicity events excludes
patients where data was unavailable (for full results see supplementary Tables R1eR9).
M.R. Ferreira et al. / Clinical Oncology xxx (xxxx) xxx6factors related to repair/recovery, (3) dose-points were not
radiobiologically equivalent if using a ‘one-ﬁts-all’ late ef-
fect a/b ratio of 3 Gy [31].
Numbers of patients with late grade 2þ toxicity were
low. For completeness, comparisons using mild toxicity
thresholds were carried out in parallel. Multiple statistical
tests were used, therefore requiring FDR correction. HolmPlease cite this article as: Ferreira MR et al., Dosimetry and Gastrointes
Radiotherapy in Advanced Localised Prostate Cancer, Clinical Oncology, hcorrection was chosen for its robustness. We nevertheless
pragmatically report different levels of signiﬁcance. Overall,
few results were found to be robustly signiﬁcant.
We show a relationship between the number of excee-
ded rectal constraints and late toxicity. Our results conﬁrm
previous reports showing rV50 to predict grade 2þ rectal
bleeding. However, robust relationships of higher dosestinal Toxicity Relationships in a Phase II Trial of Pelvic Lymph Node
ttps://doi.org/10.1016/j.clon.2019.02.012
Table 3
Positive associations between bowel dosimetry/toxicity
Clinician-reported toxicity
Cohort Threshold LENT-SOMA % patients
with toxicity
RTOG % patients
with toxicity
CFRT M N/A N/A
MS bV45 and consistency/frequency management
(P ¼ 0.01, dM ¼ 52.7)
6% bV45 and bowel frequency (P ¼ 0.04,
dM ¼ 16.96)
10%
bV55 and bowel frequency (P ¼ 0.03, dM ¼ 3.8) 10%
HFRT-4D M bV39 and frequency (P ¼ 0.03, dM ¼ 17.66) 30% bV39 and diarrhoea (P ¼ 0.03, dM ¼ 17.32) 25%
bV43 and diarrhoea (P ¼ 0.01, dM ¼ 7.39) 25%
bV47 and diarrhoea (P ¼ 0.002, dM ¼ 2.15) 25%
MS bV39 and frequency (P ¼ 0.02, dM ¼ 27.5) 13% bV39 and bowel frequency (P ¼ 0.04,
dM ¼ 27.17)
11%
bV43 and consistency (P ¼ 0.04, dM ¼ 8.33) 10% bV43 and diarrhoea (P ¼ 0.03, dM ¼ 24.50) 9%
HFRT-5D M bV39 and consistency (P ¼ 0.05, dM ¼ 32.59) 26% N/A
bV43 and consistency (P ¼ 0.03, dM ¼ 15.99) 26%
bV43 and frequency (P ¼ 0.05, dM ¼ 13.48) 31%
MS bV43 and consistency (P ¼ 0.04, dM ¼ 18.76) 17% N/A
Patient-reported toxicity
Urgency Loose stools Distress Crampy pain Problem
Threshold/ M MS M MS M MS M MS M MS
Cohort Y
CFRT N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
% patients
with toxicity
e e e e e e e e e e
HFRT-4D bV43
(P [ 0.006,
dM [ 7.04)
bV43
(P [ 0.009,
dM[ 8.8)
bV47 (P ¼ 0.03,
dM ¼ 1.55)
bV39 (P [ 0.009,
dM[ 24.78)
bV43 (P ¼ 0.0005,
dM ¼ 11.74)
bV47 (P ¼ 0.05,
dM ¼ 0.07)
N/A bV43 (P ¼ 0.04,
dM ¼ 4.10)
N/A N/A N/A bV39 (P ¼ 0.04,
dM ¼ 10.50)
bV43 (P [ 0.002,
dM[ 11.37)
bV39 (P ¼ 0.04,
dM ¼ 14.20)
bV43 (P [ 0.003,
dM[ 12.22)
bV47 (P ¼ 0.03,
dM ¼ 2.01)
% patients
with toxicity
41% 33% 43% e 34% e e e 54% 39%
HFRT-5D N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
% patients
with toxicity
e e e e e e e e e e
Where N/A is reported, no positive associations were found.Where P 0.01, results are in bold.Where results were signiﬁcant after Holm correction, results are bold and italicized. M
¼ mild threshold (symptomatic patients are deﬁned as having mild or worse symptoms). MS ¼ moderate/severe (symptomatic patients are deﬁned as having moderate or worse
symptoms). % of patients with toxicity events excludes patients where data was unavailable (for full results see supplementary Tables R1eR9).
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Fig 2. Mean volumes per dose-point by cohort and relationship with dose-volume constraints for Radiation Therapy Oncology Group (RTOG)
(AeC) and LENT-SOMA (DeF) bleeding emoderate/severe threshold (rectum); UCLA-PCI loose stools emild threshold (GeI; bowel); and RTOG
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M.R. Ferreira et al. / Clinical Oncology xxx (xxxx) xxx8(rV65) with bleeding were not found, as might have been
expected from previous reports [16,27,29]. Rectal dosimetry
was mostly kept under constraints and speciﬁc attention
was given to higher dose-points, reﬂecting QUANTEC
guidance [5]. The fact that the lower rectal constraint (rV50)
was exceeded more often with CFRT is probably due to the
superior rectum receiving dose from pelvic irradiation,
which was 60 Gy for the majority (67%) of patients. HFRT
cohorts received 47 Gy to the PLN, which is equivalent to 55Please cite this article as: Ferreira MR et al., Dosimetry and Gastrointes
Radiotherapy in Advanced Localised Prostate Cancer, Clinical Oncology, hGy for an a/b ratio typical of late reactions (3 Gy). This
aspect may also explain lower incidences of patients failing
constraints with HFRT.
bV43 and bV47 were signiﬁcantly predictive of diar-
rhoeal endpoints in the HFRT-4D cohort. Although non-
signiﬁcant after FDR correction, similar trends were
observed in other cohorts with clinician-reported diar-
rhoea. The number of mandatory and/or optimal bowel
constraints exceeded showed a relationship with toxicity. Atinal Toxicity Relationships in a Phase II Trial of Pelvic Lymph Node
ttps://doi.org/10.1016/j.clon.2019.02.012
Table 4
Proposed dose-volume constraints for rectum and bowel
Rectum Bowel
2 Gy/fraction 3 Gy/fraction* 2 Gy/fraction 3 Gy/fraction*
Dose
constraint (Gy)
Volume
required (%)
Dose
constraint (Gy)
Volume
required (%)
Dose
constraint (Gy)
Volume required (cm3)
Mandatory (target)
Dose
constraint (Gy)
Volume
required (cm3)
Mandatory
(target)
rV50 60 rV43 60 bV45 158 (78) bV39 158 (78)
rV60 50 rV51 50 bV50 110 (24) bV43 110 (24)
rV65 30 rV55 30 bV55 28 (14) bV47 28 (14)
rV70 15 rV59 15 bV60 6 (0) bV51 6 (0)
rV75 3 rV63 0 bV65 0 (0) bV55 0 (0)
* Constraints for the 3Gy cohorts were simply extrapolated from the 2Gy cohort in a ratio of 60/70 (reﬂecting the initial prostate treatment
dose of 70Gy) with no implicit radiobiological assumptions.
M.R. Ferreira et al. / Clinical Oncology xxx (xxxx) xxx 9study analysing the prognostic value of bowel dose-volume
metrics for acute bowel toxicity in patients undergoing
prostate and pelvic radiotherapy for high-risk PCa showed
bV40-bV50 to be predictive with CFRT, whereas higher
(bV55) and lower (bV15) dose-points were less predictive.
Interestingly, derived constraints were similar to the ones
we propose, although a whole intestinal cavity contouring
method was used [32]. Other studies also showed similar
results [33,34]. Robust dosimetric relationships with late
toxicity have proved more elusive, but, to our knowledge,
we report the largest prospectively collected patient series
to date [35,36]. Taken together, these data support the
mandatory threshold as a relevant dose limit when plan-
ning pelvic radiotherapy to avoid grade 2þ diarrhoea.
However, we also observed a relationship between
exceeding optimal constraints and toxicity. We therefore
recommend using optimal constraints as target doses and
planning objectives for pelvic IMRT to ensure minimal
gastrointestinal toxicity and that mandatory constraints
should not be compromised to ensure acceptable gastro-
intestinal side-effect rates. We propose that the optimal
bV50-CFRT/bV43-HFRT constraint should be updated to 24
cm3 instead of 17 cm3 given our results showing this level to
be more appropriate for predicting gastrointestinal side-
effects. These new ﬁndings may usefully inform clinical
trials and non-trial clinical practice.
We previously showed that moderate/severe gastroin-
testinal toxicity was reported in about a third of patients
meeting rectal constraints, whereas no gastrointestinal
side-effects were reported in 10% of patients failing six or
more constraints [27]. We observed similar relationships in
this dataset. In addition to uncertainties in reporting
dosimetry and toxicity, this result may be attributed to
patient-related and environmental factors [37e41]. More-
over, as many as 50% of patients have multiple gastroin-
testinal diagnoses when symptoms, which may be
misattributed to radiotherapy, are investigated [18].
Our data support that, when dose-volume parameters
are kept below tight constraints, gastrointestinal toxicity is
low and planning dosimetry loses predictive power for re-
sidual moderate/severe gastrointestinal toxicities in the
setting of PLN-IMRT. This conclusion suggests that if notPlease cite this article as: Ferreira MR et al., Dosimetry and Gastrointes
Radiotherapy in Advanced Localised Prostate Cancer, Clinical Oncology, hescalating radiation dose, further technical development of
radiotherapy for PCa may only achieve marginal improve-
ments in gastrointestinal toxicity outcomes unless it re-
duces the rates of patients where constraints are exceeded.
Future research needs to also incorporate contributing
biological mechanisms of radiation-induced toxicity, which
may help achieve superior clinical stratiﬁcation of patients
at risk of signiﬁcant side-effects, as suggested by other
authors.
To conclude, we provide an evidence base for safely
delivering PLN-IMRT using CFRT or HFRT. We propose the
constraints summarised in Table 4 as benchmarks for CFRT
and HFRT and that the planning goal should be to achieve
the target (optimal) bowel constraints whenever possible.Conﬂict of interest
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